AB-SA01: Phase I started

AmpliPhi began a double-blind, U.S. Phase I trial to evaluate topical AB-SA01 applied once daily for 3 days in about 12 healthy volunteers. Subjects will receive 108 or 109 plaque-forming units (PFUs)...